April 4, 2025 05:10 PM EDT
Pharma
FDA+

Trump ad­min­is­tra­tion leaves obe­si­ty cov­er­age ex­pan­sion out of new Medicare rule

Nicole DeFeudis

Editor

The Trump ad­min­is­tra­tion fi­nal­ized new poli­cies for some Medicare pro­grams on Fri­day, but left out pro­vi­sions that would have ex­pand­ed cov­er­age of an­ti-obe­si­ty drugs to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Marks was asked to pro­vide non-ex­is­tent vac­cine risk da­ta: WSJ

No­vavax’s held-up ap­proval pack­age may sig­nal warn­ing for Covid vac­cine mak­ers

Kennedy team de­fends Marks fir­ing, while 20% of staff cuts may be 'mis­takes'

Chi­na's re­tal­ia­to­ry tar­iffs on US could mean more head­winds for drug­mak­ers

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times